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Abstract 
An irreversible ErbB family blocker is expected to inhibit tumors with activating 
epidermal growth factor receptor (EGFR) mutations more strongly than reversible 
EGFR tyrosine kinase inhibitors and to overcome acquired resistance to the T790M 
secondary mutation. Eleven-week-old transgenic mice with Egfr exon 19 deletion 
mutation were treated with afatinib, gefitinib, or vehicle for 4 weeks. All mice were 
sacrificed at 15 weeks of age, and the number of superficial left lung tumors with a long 
axis exceeding 1 mm was counted. The afatinib-treated group had significantly fewer 
tumors than the vehicle group (P < 0.01) and tended to have fewer tumors than the 
gefitinib-treated group (P = 0.06). Pathologically, gefitinib-treated mice had clearer, 
more nodular tumors than afatinib-treated mice. Immunoblotting showed that afatinib 
suppressed not only pEGFR but also pHER2, and induced apoptosis for longer periods 
than gefitinib. Subsequently, when each drug was administered 5 days per week until 
death, afatinib significantly enhanced mouse survival compared with gefitinib (median 
survival time: 456 days versus 376.5 days; logrank test, P < 0.01). Finally, the 
combination of afatinib with bevacizumab was found to be superior to either drug alone 
in exon 19 deletion/T790M and L858R/T790M xenograft tumors. Overall, afatinib was 
more potent than gefitinib in tumors harboring an exon 19 deletion mutation, and the 
combination of afatinib with bevacizumab efficiently suppressed tumors harboring the 
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T790M secondary mutation. 
 
Introduction 
The selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 
(TKIs) gefitinib and erlotinib have shown clinical responses in patients with advanced 
non-small cell lung cancer (NSCLC), especially in those with tumors harboring 
activating EGFR mutations (1-3). Five prospective randomized clinical trials showed 
that gefitinib and erlotinib as initial treatments for EGFR-mutant NSCLC improved 
progression-free survival compared with chemotherapy (4-8). Most of the mutations in 
these studies were a deletion in exon 19 or a point mutation in exon 21 (L858R).  
Following erlotinib treatment, patients with an exon 19 deletion showed 
significantly improved response rate, progression-free survival, and overall survival 
compared with those with the L858R mutation (9). Recently, Won et al. summarized the 
differences in clinical benefits between the two mutation types using data from 12 
studies (10) and suggested that patients with an exon 19 deletion might benefit more 
from gefitinib or erlotinib treatment compared with those with the L858R mutation.  
Regardless of having the deletion or L858R mutation, the majority of patients with 
EGFR-mutant NSCLC are initially sensitive to EGFR TKI, but subsequently become 
resistant to it (11). In such patients, approximately half have tumors with a secondary 
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T790M mutation in exon 20 of EGFR (12-15) and around	 20% have tumors with 
amplifications of the MET gene (16-18). For the former group, irreversible 
second-generation EGFR inhibitors such as afatinib have been introduced. Afatinib was 
shown to be effective in tumor cells and a transgenic mouse model with an L858R point 
mutation with or without a T790M secondary mutation (19-22). Although the 
effectiveness of this agent for tumor cells with an EGFR exon 19 deletion mutation was 
shown in vitro (23), no preclinical studies using transgenic mice have yet been reported. 
Moreover, a study by Sos et al. found limited efficacy of afatinib monotherapy in 
T790M-mutated cells (24). To overcome this, the combination of EGFR TKI with a 
monoclonal antibody has been evaluated; for example, afatinib with an EGFR-specific 
antibody such as cetuximab, and gefitinib with a vascular endothelial growth 
factor-specific antibody such as bevacizumab (22, 25). 
In this study, we investigated the in vitro efficacy of afatinib against tumor cells 
with activating EGFR mutations with or without the T790M mutation and evaluated it 
in combination with bevacizumab against xenograft tumors harboring the T790M 
mutation. In addition, we compared the effectiveness of afatinib with that of gefitinib in 
EGFR transgenic mice. 
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Materials and Methods 
Cell culture and growth inhibition assay in vitro 
The pulmonary adenocarcinoma cell lines PC-9 and H1975 were purchased from 
Immuno-Biological Laboratories (Takasaki, Gunma, Japan) and from the American 
Type Culture Collection (Manassas, VA), respectively. PC-9 was derived from an 
untreated Japanese patient with pulmonary adenocarcinoma carrying an in-frame 
deletion in EGFR exon 19 (delE746-A750) (26). H1975 was derived from a female 
never smoker patient with pulmonary adenocarcinoma carrying exon 21 missense 
mutation (L858R) and exon20 missense mutation (T790M) (27). Gefitinib-resistant 
RPC-9 cells were established in our laboratory by continuously exposing PC-9 cells to 
gefitinib (14). PC-9 cells were sensitive to EGFR TKI, while RPC-9 cells carrying 
delE746-A750 with T790M and H1975 cells carrying L858R with T790M were EGFR 
TKI-resistant. All the cell lines used were authenticated. 
Cells were cultured at 37°C with 5% CO2 in RPMI 1640 medium supplemented 
with 10% heat-inactivated fetal bovine serum. Growth inhibition was determined using 
a modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
(28). Cells were placed on 96-well plates at a density of 2,000 per well and continuously 
exposed to each drug for 96 h. MTT was then added to each well, and the cells were 
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incubated for 4 hours at 37°C before measurement of absorbance at 570 nm of cell 
lysate by a microplate reader (Bio-Rad, Model 680, USA). Absorbance values were 
expressed as a percentage of that for untreated cells. The drug concentration required to 
inhibit the growth of tumor cells by 50% (IC50) was used to evaluate the effect of the 
drug. Each assay was performed in triplicate. 
 
Reagents and antibodies 
Afatinib (Fig. 1A) was kindly provided by Boehringer Ingelheim (Mannheim, 
Germany). Gefitinib and bevacizumab were purchased from Everlth Co., Ltd. 
(Okayama, Japan).  Rabbit antisera against EGFR, phospho-specific (p) EGFR 
(pY1068), human epidermal growth factor receptor (HER)2, pHER2 (pY877), pHER3 
(pY1289), mitogen-activated protein kinase (MAPK), pMAPK (pT202/pY204), Akt, 
pAkt (pSer473), PARP, cleaved caspase 3, GAPDH, and β-actin were purchased from 
Cell Signaling Technology (Tokyo, Japan). Anti-HER3 monoclonal antibody was 
purchased from Upstate Biotechnology (Lake Placid, NY). 
 
Immunoblotting analysis 
Cells or frozen tissue were lysed in radioimmunoprecipitation assay buffer [1% Triton 
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X-100, 0.1% SDS, 50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1 mmol/L EDTA, 
1 mmol/L EGTA, 10 mmol/L β-glycerolphosphate, 10 mmol/L NaF, 1 mmol/L sodium 
orthovanadate-containing protease inhibitor tablets (Roche Applied Sciences GmbH, 
Mannheim, Germany). Proteins were separated by electrophoresis on polyacrylamide 
gels, transferred onto nitrocellulose membranes, and probed with specific antibodies 
followed by detection with Enhanced Chemiluminescence Plus (GE Healthcare 
Biosciences, Tokyo, Japan).  
 
Animal husbandry and drug treatment 
We generated transgenic mice constitutively expressing the delE748-A752 version of 
mouse Egfr (29) and the L858R version of human EGFR (30) in the lung only using the 
SP-C promoter, which is exclusively activated in type 2 alveolar epithelial cells. The 
transgenic mice had no distant metastases (29, 30). All animals were kept under 
pathogen-free conditions with abundant food and water as specified in the guidelines of 
the Department of Animal Resources, Okayama University Advanced Science Research 
Center, Japan. Afatinib (5 mg/kg) or gefitinib (5 mg/kg) were given once daily, 5 days 
per week as a suspension by gavage. Afatinib was prepared in 0.5 w/v% methyl 
cellulose and gefitinib was prepared in 1% polysorbate 80 by homogenization and 
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ball-milled with glass beads for 24 h. After 4 weeks administration of each drug, the 
mice were sacrificed by cervical dislocation and the lungs excised and the numbers of 
tumors on the surface of the left lungs were counted. The right lungs were used for 
protein extracts. All experiments involving animals were performed under the auspices 
of the Institutional Animal Care and Research Advisory Committee at the Department 
of Animal Resources, Okayama University Advanced Science Research. 
 
Histology 
Animals were sacrificed by cervical dislocation and the lungs, the skins, the intestines 
and the livers were excised. The organs were inflated with 10% paraformaldehyde in 
phosphate-buffered saline (PBS), fixed in 10% paraformaldehyde overnight at room 
temperature, embedded in paraffin, and sectioned every 5 µm (West Japan Pathology, 
Okayama, Japan). The sections were stained with hematoxylin-eosin.  
 
Xenograft model 
Female athymic mice at 7 weeks of age were purchased from Japan Charles River Co.  
All mice were provided with sterilized food and water and housed in a barrier facility 
under a 12-h light/dark cycle. Cells (2 × 106) were injected s.c. into the backs of the 
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mice. When the tumor volume exceeded 100 mm3, the mice were randomly assigned to 
one of five groups (5 to 6 mice per group) that received either vehicle, 10 mg/kg 
afatinib, 5 mg/kg bevacizumab, 10 mg/kg afatinib plus 5 mg/kg bevacizumab or 10 
mg/kg gefitinib plus 5 mg/kg bevacizumab. Vehicle, gefitinib and afatinib were 
administered once daily, 5 days per week by gavage. Bevacizumab (5 mg/kg) was 
administered twice a week i.p. Tumor volume (width2 × length/2) was determined twice 
a week. Administration of each drug was continued during the experimental term (53 
days for RPC-9 cells and 40 days for H1975 cells). 
 
Statistical analysis 
Statistical analysis was performed using the SPSS Base System™ and Advanced 
Statistics™ programs (SPSS, Chicago, IL). Group differences were compared using 
Student’s t-test. Survival time was defined as the period from initiation of treatment to 
death or last follow-up evaluation. Overall survival curves were calculated using the 
Kaplan–Meier method. P < 0.05 was considered statistically significant. 
 
Results 
Afatinib suppressed PC-9 and RPC-9 cells at lower concentrations than gefitinib 
The mean IC50s ± standard error (SE) of afatinib for PC-9 cells and RPC-9 cells was 
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0.00032 ± 0.00016 µmol/L and 0.164 ± 0.07784 µmol/L, respectively, which was less 
than that of gefitinib for PC-9 (0.0033 ± 0.01074 µmol/L) and RPC-9 cells (11.45 ± 
2.77717 µmol/L) (Fig. 1B). pEGFR, pAKT, and pERK in PC-9 cells were suppressed 
by both treatment with afatinib (1 nmol/L) and with gefitinib (100 nmol/L) (Fig. 1C). In 
RPC-9 cells, afatinib was 100-fold less active (100 nmol/L) than in parental cells, while 
gefitinib was ineffective (10,000 nmol/L) (Fig. 1D). In addition, 1 nmol/L and 100 
nmol/L of afatinib completely inhibited pHER2 in PC-9 cells and RPC-9 cells, 
respectively (Fig. 1E). Interestingly, gefitinib also suppressed pHER2 in both cell types 
at concentrations that could suppress pEGFR (Fig. 1E). These results suggest that 
afatinib was effective in PC-9 and RPC-9 cells at lower concentrations than gefitinib. 
 
Afatinib may be more effective than gefitinib for treatment of lung cancer induced 
by the EGFR mutation in exon 19 
We next investigated the effect of afatinib on lung tumors induced by the activating 
EGFR mutation in vivo. Eleven-week-old transgenic mice with an exon 19 deletion 
mutation were treated with oral afatinib (5 mg/kg/day), gefitinib (5 mg/kg/day), or 
vehicle alone from 11 to 15 weeks of age. No significant difference was found between 
the three groups with respect to weekly measurement of body weight (Fig. 2A). We 
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previously reported that no interstitial lung disease was found in the mice treated with 
gefitinib (29) and no other toxicities of skin, intestine and liver developed in the present 
study (Supplemental Fig. 1).   
All mice were sacrificed at 15 weeks of age and the number of superficial left lung 
tumors with a long axis exceeding 1 mm was determined to be 0.12 ± 0.13, 1.25 ± 0.60, 
and 9.00 ± 1.5 in the afatinib-treated group, gefitinib-treated group, and vehicle group, 
respectively (Fig. 2B). This represented a significant difference between the 
afatinib-treated group and vehicle group (P < 0.01) and indicated a tendency for fewer 
tumors with afatinib than with gefitinib (P = 0.06). Pathologically, gefitinib-treated 
mice had clearer, more nodular tumors than afatinib-treated mice (Fig. 2C). We 
performed the same experiment using transgenic mice with the L858R EGFR exon 21 
point mutation and observed no superficial tumors in gefitinib- or afatinib-treated mice 
and no toxicity (Fig. 2D and 2E). In addition, there was no clear tumor formation in 
pathological samples in any group (Fig. 2F). Toxicities in lung, skin, intestine and liver 
were not observed in the L858R transgenic mice treated with afatinib (Supplemental Fig. 
1). 
 
Afatinib suppressed EGFR and HER2 and induced apoptosis for longer than 
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gefitinib 
Immunoblotting was performed to confirm the histological response at the protein level. 
The lungs of 11-week-old transgenic mice showed overexpression of both pEGFR and 
pHER2 (Fig. 3A), consistent with our previous data (29, 31). Subsequently, 
14-week-old mice were sacrificed at the indicated time after single administration of 
each drug. In gefitinib-treated mice, pEGFR was suppressed at 2 and 6 h but was 
recovered at 10 h (Fig. 3B). On the other hand, in afatinib-treated mice, pEGFR was 
suppressed at 2, 6, and 10 h and was partially recovered at 14 and 18 h (Fig. 3B). At 14 
h, pEGFR expression was higher in the gefitinib-treated mice and lower in the 
afatinib-treated mice than in mice without treatment. In the gefitinib-treated mice, 
pHER2 was decreased at 2 and 6 h but was recovered by 10 h (Fig. 3B), whereas in 
afatinib-treated mice, it was suppressed from 2 to 18 h (Fig. 3B). These results were 
comparable with those in vitro (Fig. 1E).  
Cleaved PARP and cleaved caspase 3 were analyzed to examine the effects on 
apoptosis. This was induced at 6 and 10 h only in gefitinib-treated mice but was 
observed from 6 to 18 h in afatinib-treated mice (Fig. 3C). It might be due to the 
difference of duration of suppression of pEGFR and pHER2 in comparison with control 
(2 to 6 h versus 2 to 18 h). These results suggest that afatinib is more effective than 
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gefitinib because it suppresses not only pEGFR but also pHER2 and induces apoptosis 
over a longer period than gefitinib. 
 
Effect of afatinib on the survival of transgenic mice 
Short-term (4 weeks) administration of afatinib tended to be more effective than that of 
gefitinib in the lung cancer model induced by a deletion mutation in exon 19 (Fig. 2B, 
2C). To investigate the efficacy of long-term afatinib treatment, we randomly assigned 
7-week-old transgenic mice to receive vehicle alone (n=13), gefitinib (5 mg/kg/day, 
n=14), or afatinib (5 mg/kg/day, n=15) and orally administered each drug for 5 days per 
week until toxicity or death. All mice in the control group died, with a median survival 
time of 119 days. We also investigated change of the tumor sizes in transgenic mice 
after the treatment using computed tomography (Supplemental Fig. 2A). The tumors 
were responded to afatinib or gefitinib. Tumor reduction in afatinib-treated mice was 
more profound than that in gefitinib-treated mice (Supplemental Fig. 2B). 
Survival curves of gefitinib-treated and afatinib-treated mice are shown in Fig. 4A. 
Afatinib treatment significantly enhanced the survival of transgenic mice (logrank test, 
P < 0.01), with a median survival time of 456 days compared with 376.5 days for 
gefitinib-treated mice (Fig. 4A). No toxic death was observed in any mice. Four weeks 
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after the initiation of treatment, body weight in the control group was significantly 
lower than in the gefitinib and afatinib groups (Fig. 4B). Gefitinib-treated mice lost a 
significant amount of weight compared with afatinib-treated mice after 34 weeks (Fig. 
4B), which is likely to be a result of tumor progression. 
 
Combination of afatinib with bevacizumab in T790M-mutant tumors 
We hypothesized that the combination of afatinib with bevacizumab would be effective 
for treating tumors harboring the T790M mutation. Although afatinib or bevacizumab 
alone was ineffective against RPC-9 xenograft tumors (Fig. 5A), the combination of 
afatinib with bevacizumab inhibited tumor growth more efficiently. An H1975 
xenograft tumor was then used to determine whether the superiority of the combination 
therapy could be confirmed in other cancer cells harboring the T790M mutation; again 
the drug combination proved to be effective (Fig. 5B). Subsequently, we compared the 
effect of gefitinib and afatinib when combined with bevacizumab in xenograft models 
of RPC-9 and H1975 (Supplemental Figure 3A, B). Actually, both combinations 
significantly suppressed tumor growth compared with vehicle alone (day 21 in RPC-9; 
days 5, 8, 12 and 15 in H1975). Although the tumor volume treated with bevacizumab 
and afatinib was consistently smaller than that treated with bevacizumab and gefitinib, 
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there were not significant differences in any points. 
 To examine why the combination of bevacizumab with afatinib was more 
effective than afatinib alone or bevacizumab alone (Fig. 5A), we analyzed the RPC-9 
tumors by Western blotting. The expression levels of pEGFR, pAKT and cleaved 
caspase 3 were similar between afatinib alone and the combination of bevacizumab with 
afatinib (Supplemental Fig. 4A). Since bevacizumab alone did not affect expression of 
pEGFR, pAKT and cleaved caspase 3, we evaluated neovascularization using 
immunohistochemistry (Supplemental Fig. 4B). CD31-positive blood vessels in tumors 
treated by bevacizumab alone or combination of bevacizumab with afatinib were 
significantly reduced compared with tumors treated by vehicle or afatinib alone. These 
results suggested that the combination therapy might be effective because the 
suppression effect of neovascularization by bevacizumab was added to tumor growth 
inhibition by afatinib. 
 
Discussion 
Irreversible EGFR TKIs such as afatinib are expected to inhibit tumors with activating 
EGFR mutations more strongly than reversible EGFR TKIs and to overcome the 
acquired resistance attributable to the T790M secondary mutation. We found that 
afatinib was more potent than gefitinib in tumors harboring an exon 19 deletion 
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mutation and that the combination of afatinib with bevacizumab was useful in the 
treatment of tumors harboring the T790M secondary mutation. 
Afatinib was effective at lower concentrations than gefitinib in PC-9 cells (Fig. 1B, 
1C), although interestingly, the concentration of gefitinib (100 nmol/L) that could 
suppress pEGFR in PC-9 cells also inhibited pHER2 (Fig. 1E). This presumably reflects 
the temporary suppression of the EGFR/HER2 heterodimer by gefitinib. However, the 
ErbB family blocker afatinib suppressed pHER2 at a lower concentration (1 nmol/L) 
than gefitinib (Fig. 1E).  
Subsequently, we investigated the efficacy of afatinib in a transgenic mouse model 
and found it to be more effective than gefitinib in the lung of exon 19 deletion mutant 
mice (Fig. 2C). Afatinib-treated mice also suppressed pEGFR and pHER2 for longer 
than gefitinib-treated mice, and afatinib appeared to induce apoptosis at 14 and 18 h 
despite partial recovery of the EGFR signal (Fig. 3C). Finally, afatinib significantly 
prolonged the survival of transgenic mice compared with gefitinib (Fig. 4A), indicating 
its higher potency in tumors with an EGFR exon 19 deletion mutation. We await the 
findings of the LUX-Lung 7 trial (NCT01466660), a phase IIb trial of afatinib versus 
gefitinib in the treatment of 1st line EGFR mutation-positive lung adenocarcinoma, to 
determine whether the data are correlated with our observations. 
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Afatinib was also shown to be effective at lower concentrations (by approximately 
1/100th) than gefitinib in both parent and resistant tumor cell lines harboring the T790M 
secondary mutation, but it appeared that such tumor cells might be resistant to both 
afatinib and gefitinib. In fact, in a phase IIb/III randomized trial, 29 (7%) of 390 
patients who initially failed reversible EGFR TKI treatment had a partial response to 
afatinib (32). Sos et al. reported a dramatic reduction in the potency to 
gatekeeper-mutated EGFR of irreversible EGFR TKIs compared with single activating 
EGFR mutations (24). The present results are consistent with this (Fig. 1), suggesting 
that irreversible EGFR TKI monotherapy is insufficient for overcoming resistance by 
gatekeeper mutations. 
The combination of afatinib with an EGFR-specific antibody (cetuximab) was 
found to induce shrinkage of erlotinib-resistant tumors harboring the T790M mutation 
(22) as well as be effective in patients with the T790M mutation (33). Moreover, we 
previously showed in vivo that the combination of gefitinib with the vascular 
endothelial growth factor inhibitor bevacizumab inhibited the growth of tumors 
harboring the T790M mutation more efficiently than gefitinib alone (25). In the present 
study, we demonstrated that the combination of afatinib with bevacizumab in exon 19 
deletion/T790M (RPC-9) and L858R/T790M (H1975) xenograft tumors was superior to 
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each drug alone.  
This study had some limitations. Firstly, the effect of afatinib on tumorigenesis was 
not examined. We previously reported that the transgenic mice developed atypical 
adenomatous hyperplasia at age 4 weeks and multifocal adenocarcinoma of varying 
sizes at age 7 weeks (30). Administration of gefitinib to 3-week-old transgenic mice for 
1 week before carcinogenesis reduced the amount of phosphorylated EGFR in the lungs 
of the mice to the baseline level. Gefitinib inhibited tumorigenesis completely in the 
mouse model. Although we expect afatinib may have chemopreventive effect, it 
remains unclear from our study. In the present study, 11-week-old transgenic mice were 
treated with oral afatinib, gefitinib, or vehicle alone from 11 to 15 weeks of age (Fig. 2). 
Meanwhile, to investigate the efficacy of long-term afatinib treatment, we randomly 
assigned 7-week-old transgenic mice to receive vehicle alone, gefitinib, or afatinib and 
orally administered each drug (Fig. 4). Since transgenic mice developed 
adenocarcinoma at age 7 weeks, we think this study showed successful treatment for 
lung cancer. From the point of view of chemopreventive effect of afatinib, we should 
administer the drug to 3-week old transgenic mice. Further study including analysis of 
molecular targets should be needed. Secondary, we could not show whether the drug 
doses used for mouse studies were clinically relevant. The clinical data including 
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recommended dose of afatinib were not available when we initiated this study. Now, we 
know afatinib was administered to human at the dose of 50 mg/day although the dose of 
gefitinib was 250 mg/day. In addition, the pharmacokinetics and pharmacodynamics in 
the mouse are usually different from those in human. Those are reasons why we 
administered the same doses of both drugs (10 mg/kg for xenograft mice; 5 mg/kg/day 
for transgenic mice). 
In conclusion, afatinib was more potent than gefitinib in the treatment of lung 
adenocarcinoma with an EGFR exon 19 deletion mutation. Moreover, afatinib in 
combination with bevacizumab may overcome the resistance attributed to the T790M 
secondary mutation. 
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Figure legends 
Figure 1. Effects of gefitinib and afatinib on the growth of PC-9 and RPC-9 cells in 
vitro. 
A, Drug structures of afatinib and gefitinib. B, Drug sensitivity. Cells were seeded 
(2,000 per well) on 96-well plates and were cultured for 96 h in complete medium 
containing various concentrations of gefitinib and afatinib, after which cell viability was 
assessed as described in Materials and Methods. Points, mean values of triplicate 
cultures; Bars, SE. C, D, Effects of each drug on the phosphorylation status of EGFR 
and its downstream signaling in (C) PC-9 and (D) RPC-9 cells. Cells were incubated 
with various concentrations of each drug for 2 h and cell lysates were prepared and 
subjected to immunoblot analysis with antibodies to phosphorylated or total forms of 
EGFR, STAT3, AKT or ERK as well as with those to β-actin. E, Inhibition of HER2. 
PC-9 and RPC-9 cells were incubated with various concentrations of each drug for 2 h 
and cell lysates were prepared and subjected to immunoblot analysis with antibodies to 
phosphorylated or total forms of HER as well as with those to β-actin. 
 
Figure 2. Effects of gefitinib or afatinib in transgenic mice. 
A, Changes in body weight in each group. Transgenic mice with Egfr exon 19 deletion 
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mutation were administered each drug 5 days per week for 4 weeks. Body weight was 
measured once a week. Bars, SE. B, Number of superficial left lung tumors with the 
long axis exceeding 1 mm in each group. Tumor numbers were counted after 4 weeks 
administration of each drug. Bars, SE. *, p<0.01, for vehicle versus either gefitinib or 
afatinib. C, The left lung after 4 weeks administration of each drug. The sections were 
stained with hematoxylin-eosin. D, Changes in body weight in each group. Transgenic 
mice with EGFR exon 21 L858R mutation were administered each drug 5 days per 
week for 4 weeks. Body weight was measured once a week. Bars, SE. E, Number of 
superficial left lung tumors with the long axis exceeding 1 mm in each group. Tumor 
numbers were counted after 4 weeks administration of each drug. Bars, SE. *, p<0.01, 
for vehicle versus either gefitinib or afatinib. F, The left lung after 4 weeks 
administration of each drug. The sections were stained with hematoxylin-eosin. 
 
Figure 3. Comparison of gefitinib and afatinib in the suppression of pEGFR and pHER2 
in transgenic mice with an exon 19 deletion mutation.  
A, Protein levels in the lungs of untreated 14-week-old transgenic (Tg) and control mice 
(WT) examined by immunoblotting. Each 14-week-old mouse was sacrificed and 
proteins were extracted from the right lung. GAPDH was used as a loading control. 
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Phosphorylated or total forms of EGFR, HER2 and HER3 were examined. B, Protein 
levels in the right lungs of 14-week-old mice sacrificed at the indicated points. GAPDH 
was used as a loading control. Phosphorylated or total forms of EGFR, HER2 and were 
examined. C, Expression of the apoptosis-related proteins cleaved PARP and cleaved 
caspase 3 examined by immunoblotting in 14-week-old mice sacrificed at 2, 6, 10, 14, 
and 18 h after single administration of each drug.  
 
Figure 4. Long-term effects of gefitinib or afatinib in transgenic mice. 
A, Survival curves of vehicle (solid line), gefitinib-treated (dotted line) and 
afatinib-treated (broken line) mice. + indicates the censored mouse. B, Change in body 
weight of vehicle, gefitinib-treated and afatinib-treated mice. Bars, SE. *, p<0.05, for 
vehicle versus either gefitinib or afatinib (left) and gefitinib versus afatinib (right). 
 
Figure 5. Xenograft model. 
A, B, Growth curves of (A) RPC-9 and (B)  H1975 xenograft tumors in animals 
receiving oral administration of 10 mg/kg/d afatinib 5 times per week or i.p. 
administration of 5 mg/kg bevacizumab twice a week. Difference in tumor volume was 
compared using Student’s t test. Bars, SE. *, p<0.05, for the combination of afatinib 
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with bevacizumab versus other treatments (vehicle, afatinib alone, and bevacizumab 
alone. 
